NASDAQ : MRNA
Moderna, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 221.72 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 88.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 88.52B |
| Enterprise Value | 82.90B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 399.24M |
| Shares Outstanding | 399.24M |
| Shares Change (YoY) | +1.94% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 6.74% |
| Owned by Institutions (%) | 80.45% |
| Float | 371.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.73 |
| Forward PS | 46.39 |
| PB Ratio | 13.08 |
| P/TBV Ratio | 13.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 37.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.29 |
| Quick Ratio | 2.07 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -39.00% |
| Return on Assets (ROA) | -13.26% |
| Return on Invested Capital (ROIC) | -75.99% |
| Return on Capital Employed (ROCE) | -28.91% |
| Weighted Average Cost of Capital (WACC) | 10.16% |
| Revenue Per Employee | $474,043 |
| Profits Per Employee | -$670,426 |
| Employee Count | 4,700 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 14.23 |
Taxes
| Measure | Value |
|---|
| Income Tax | 64.00M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +797.65% |
| 50-Day Moving Average | 182.49 |
| 200-Day Moving Average | 86.58 |
| Relative Strength Index (RSI) | 57.33 |
| Average Volume (20 Days) | 19,524,763 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 32.60M |
| Short Previous Month | 30.86M |
| Short % of Shares Out | 8.17% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 1.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.23B |
| Gross Profit | -1.47B |
| Operating Income | -2.44B |
| Pretax Income | -3.09B |
| Net Income | -3.15B |
| EBITDA | -2.20B |
| EBIT | -2.44B |
| Loss Per Share | -$8.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.14B |
| Total Debt | 1.29B |
| Net Cash | 5.62B |
| Net Cash Per Share | $14.08 |
| Equity (Book Value) | 6.76B |
| Book Value Per Share | 16.94 |
| Working Capital | 3.28B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -1.07B |
| Capital Expenditures | -171.00M |
| Depreciation & Amortization | 241.00M |
| Net Borrowing | 578.00M |
| Free Cash Flow | -1.24B |
| FCF Per Share | -$3.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | -66.02% |
| Operating Margin | -109.34% |
| Pretax Margin | -138.55% |
| Profit Margin | -141.43% |
| EBITDA Margin | -98.52% |
| EBIT Margin | -109.34% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.94% |
| Shareholder Yield | -1.94% |
| Earnings Yield | -3.61% |
| FCF Yield | -1.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $138.37 |
| Price Target Difference | -37.59% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 19.80% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.62 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |